GrowthWorks Canadian Fund

case study / By

GrowthWorks Canadian Fund

Transaction Overview

Rosetta Capital completed a secondary transaction involving debt and equity to secure a portfolio of US and Canadian life sciences assets from GrowthWorks, a Canadian fund manager.

 

Selected exits from the portfolio include the sale of Gemin X to Cephalon, Ambit Pharmaceuticals to Daiichi Sankyo and Aegera to Pharmascience.

Supporting portfolio companies for the next growth phase

Rosetta Capital supported the portfolio companies acquired in the transaction through the growth phase and made several follow-on investments.


Rosetta partners joined the boards of acquired portfolio companies and were actively involved in strategic decision making, leading to multiple exits.

The basket transaction being announced today is a further important milestone for the Company and delivers against that communicated goal. We are delighted to welcome Rosetta Capital as co-shareholders in ReNeuron, Immunocore and Inivata and we welcome their expertise and experience. We are looking forward to continuing to work with the management teams of the Company’s holdings in delivering sustainable value and positive long-term shareholder returns.”

Tim Creed and Ben Wicks

Portfolio Managers at Schroder UK Public Private Trust plc

Read press release
Terms & conditions
Cookie policy
Privacy policy

Registered in England No. 3941653 | VAT No. GB 765 3567 96

© 2017 Rosetta Capital Limited | Authorised and regulated by the Financial Conduct Authority

Website by Instinctif Partners
Rosetta Capital
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.